Can I read Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed Drugs on EtoBox?

Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed Drugs by Veronique Michaud; Pamela Dow; Sweilem B. Al Rihani; Malavika Deodhar; Meghan Arwood; Brian Cicali; Jacques Turgeon is a Medicine article available to read on EtoBox.

What is Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed Drugs about?

The risk‐benefit ratio associated with the use of repurposed drugs to treat severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2)‐related infectious coronavirus disease 2019 (COVID‐19) is complicated because benefits are awaited, not proven. A thorough literature search was conducted to source information on the pharmacological properties of 5 drugs and 1 combination (azithromycin, chloroquine, favipiravir, hydroxychloroquine, remdesivir, and lopinavir/ritonavir) repurposed to treat COVID‐19. A risk assessment of drug‐induced long QT syndrome (LQTS) associated with COVID‐19 repurposed drugs was performed and compared with 23 well‐known torsadogenic and 10 low torsadogenic risk compounds. Computer calculations were performed using pharmacokinetic and pharmacodynamic data, including affinity to block the rapid component of the delayed rectifier cardiac potassium current (I~Kr~) encoded by the human __ether‐a‐go‐go__ gene (__hERG__), propensity to prolong cardiac repolarization (QT interval) and cause torsade de pointes (TdP). Seven different LQTS indices were calculated and compared. The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database was

Who reads Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed Drugs?

Author

Veronique Michaud; Pamela Dow; Sweilem B. Al Rihani; Malavika Deodhar; Meghan Arwood; Brian Cicali; Jacques Turgeon

Publisher

Wiley

Published

2020

Language

EN

Field

Medicine (Health Sciences)